8-K: Scilex Holding Subsidiary Semnur Amends Merger Agreement with Denali Capital Amid Nasdaq Delisting

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, amends its merger agreement with Denali Capital Acquisition Corp. to address Nasdaq delisting and extend key dates.

Summary

• Scilex Holding Company's subsidiary, Semnur Pharmaceuticals, has amended its merger agreement with Denali Capital Acquisition Corp.
• The amendment addresses the delisting of Denali's securities from the Nasdaq Capital Market and their subsequent quotation on the OTC Markets Group.
• The amendment requires Denali to extend the period to complete the business combination to December 11, 2025, or another mutually agreed date.
• The Outside Date for the merger has been extended to September 30, 2025, with a possible further extension if an Extension Amendment is in effect.
• Denali will file a definitive proxy statement/final prospectus with the SEC and mail it to its shareholders.
• The merger requires approval from both Semnur's stockholders and Denali's shareholders.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the amendment allows the merger process to continue, the Nasdaq delisting and the need for an extension introduce uncertainty.

Positives

• The amendment allows the merger process to continue despite Denali's securities being delisted from Nasdaq.
• Extending the Outside Date provides more time to complete the merger.
• The continued listing or quotation of Domesticated Parent Common Shares and Domesticated Parent Warrants on the applicable Stock Exchange through the Effective Time.

Negatives

• Denali's securities being delisted from Nasdaq could negatively impact investor confidence.
• The need for an extension suggests potential challenges in completing the merger within the original timeframe.

Risks

• General economic, political, and business conditions could impact the merger.
• Legal proceedings could be instituted against the parties following the announcement of the Business Combination.
• An unsolicited offer from another party could interfere with the Business Combination.
• Failure to obtain approval from stockholders of Semnur or shareholders of Denali.
• Failure to realize the anticipated benefits of the Business Combination.
• Redemption requests made by Denali's shareholders could impact the deal.
• Inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq or OTC Markets.
• Costs related to the Business Combination.

Future Outlook

The companies aim to complete the merger, but the timeline is subject to shareholder approvals, regulatory requirements, and market conditions.

Industry Context

The SPAC market has seen increased scrutiny and volatility, making deal closures more challenging. Delistings can occur when companies fail to meet listing requirements, which can impact investor confidence and deal terms.

Comparison to Industry Standards

• SPAC mergers are often compared to traditional IPOs as alternative routes to public listing.
• Delays and amendments are not uncommon in SPAC transactions due to regulatory hurdles and market volatility.
• Companies like Digital World Acquisition Corp. (DWAC) have faced similar challenges with deal closures and regulatory scrutiny.
• The success of the merger will depend on factors such as market conditions, investor sentiment, and the combined company's ability to execute its business plan.

Stakeholder Impact

• Shareholders of Denali and Scilex/Semnur will be impacted by the merger and its potential success or failure.
• Employees of Semnur could be affected by changes resulting from the merger.
• The merger could impact the competitive landscape and relationships with customers and suppliers.

Next Steps

• Denali will file and mail a definitive proxy statement/final prospectus to its shareholders.
• Denali will hold an extraordinary general meeting of shareholders to approve the Business Combination.
• Semnur's stockholders will need to approve the merger.
• The companies will work to satisfy all closing conditions and complete the merger.

Key Dates

Keywords

Merger Agreement, Semnur Pharmaceuticals, Denali Capital Acquisition Corp., Scilex Holding Company, Business Combination, Nasdaq Delisting, OTC Markets, Amendment, Proxy Statement